abc biopply AG, Europe's fully integrated Organoid CRO, and Panome Bio, a leading US multi-omics CRO specializing in Next-Generation Metabolomics and integrated multi-omics analysis, today announced the signing of a strategic collaboration agreement aimed at expanding the availability of standardized, human-relevant preclinical data generation and advanced molecular analytics for pharmaceutical an

Preclinical program will evaluate Topadur’s locally acting compounds, including clinical-stage TOP-N53, in dystrophic epidermolysis bullosa Studies in collaboration with the Medical Center – University of Freiburg and the EB Research Institute in Salzburg

Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing investors. Proceeds will fund advancement of Nouscom’s lead asset NOUS-209, an investigational, off-the-shelf neoantigen-based cancer immunotherapy, through a global, registration-enab

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well-tolerated safety profile NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer Publication comes as iOnctura awaits readouts from

abc biopply AG, Europe's first fully integrated Organoid CRO, and VoxCell BioInnovation Inc., a Canadian company and pioneer in bioprinted vascularized and perfusable tissue technologies in drug development, today announced the signing of a Letter of Intent (LOI) to explore a strategic collaboration focused on expanding the capabilities and accessibility of advanced human-relevant preclinical mode

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

VIVA2 Expansion: ten23 health launches advanced high precision large-scale aseptic syringe, cartridge and vial filling Line 2, supporting customers through commercial scale-up.

The clearances for relapsed/refractory B-ALL, aggressive B-NHL, and systemic lupus erythematosus (SLE) mark a major milestone in the global clinical development of META 10-19, built on the company’s pioneering META 10 metabolic reprogramming platform.

ten23 health and Ypsomed today announced the next milestone in their strategic partnership on the YpsoDose wearable injector: By installing dedicated device assembly capabilities for Ypsomed's large-volume wearable injector, ten23 health is further expanding the integrated development and manufacturing offering established by the two companies. The new equipment is now finalizing qualification.

Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA designations underscores the promise of SOT106 and strengthens the program’s potential path to patients First-in-human study of SOT106 on track to be initiated in 2026

Swiss Bioscience selected as OrganTech's preferred strategic partner in Europe for regulatory development, GMP manufacturing, clinical research, and potential commercialization of the conditioned medium technology.

SOTIO Biotech today announced that the first participant has been dosed in its Phase 1/2 CADENCIA-01 clinical trial of SOT109 in colorectal cancer. SOT109 is a potentially best-in-class antibody-drug conjugate exploiting the highly promising target of CDH17 for the treatment of CRC and other gastrointestinal cancers. As the only CDH17-targeting ADC that has been granted U.S. FDA Fast Track Designa

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE 87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2 All secondary efficacy endpoints met with statistical significance Well-tolerated safety profile of deucrictibant XR demonstrated

NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury — Round Led by Neurimmune and Pureos, with Participation from Existing and New Investors, Complemented by Non-Dilutive Funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation

Collaboration will use NewBiologix’s Xcell platform to establish a scalable manufacturing foundation for Synastra’s investigational DMD gene therapy program.

Developed on US claims, validated on external ICU data and against independent clinical review, results will be presented at ERS Congress 2026.  

The collaboration brings an advanced preclinical SOD1 gene therapy program, into Institut Charcot's growing ALS pipeline, provides a concrete demonstration of ReMedys Foundation's translational model and strengthens Avrion's focus on preparing AVR-001 for clinical development.

DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027 Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operat

Avrion Therapeutics Appoints New Chief Executive Officer and Strengthens Leadership Team to Advance ALS Pipeline. Harald Petry transitions to Chairman of the Board and Chief Scientific Officer; Patrik Richard is appointed Chief Operating Officer; Ravi Sodha joins as Vice President, Business Development

Nomination recognizes the company's pioneering META 10 metabolic reprogramming platform and its clinical translation into next-generation cell therapies.

The University Hospital Cologne (Universitätsklinikum Köln, UHC) has chosen the Celonic Group as its CDMO partner for advanced process development and GMP manufacturing of its monoclonal antibody targeting Pseudomonas aeruginosa, a Gram‑negative pathogen responsible for severe hospital‑acquired infections, biofilm‑driven persistence, and rising antimicrobial resistance. The antibody progra

$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the company with capital needs through potential U.S. regulatory approval of engasertib Marks the company's transition

As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for the PharmaBlock’s 3rd Green Chemistry Symposium (GCS) to explore how green chemistry and process innovation can accelerate the decarbonization of pharmaceutical manufacturing.

People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social well-being Study results informed the design and endpoint selection of the ongoing Phase 3 CREAATE study

SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).

Volv Global has been selected as a finalist in the 2026 Fierce AI Innovation Awards, in the category AI Innovation in Real-World Evidence & Data Analytics.

Celonic AG, a Swiss-based biologics Contract Development and Manufacturing Organization (CDMO), and Leukocare AG, a leading provider of drug product development services, today announced a collaboration to support biopharmaceutical companies developing increasingly complex biologics.

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedema Explains the scientific foundation for targeting the bradykinin B2 receptor as a therapeutic strategy for additional bradykinin-mediated diseases

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the Boards of Appeal of the European Patent Office (EPO) have upheld European Patent EP 3 444 271 B1, reinforcing intellectual property protection for SOT201, the company's next-generation PD-1-targeting immunocytokine currently being evaluated in a Phase 1 clinical trial. The decision strengthens

The new digital platform reinforces CELLnTEC’s positioning as the pioneer in chemically defined, animal-free tissue culture and a leader in epithelial and skin tissue engineering

HSC-based humanized mouse model of pulmonary fibrosis achieves stable multilineage human immune engraftment without graft-versus-host disease Nintedanib treatment confirms clinically consistent drug response, validating the model for evaluation of human-specific biologics and cell therapies International patent filed under the Patent Cooperation Treaty in February 2026, with national phase entries

Cytosurge has appointed veteran biotech executive and investor Luba Greenwood, J.D., to its Board of Directors. With deep expertise across biotech, AI, and venture capital, Greenwood joins to accelerate Cytosurge’s US expansion and scale its Same-Cell Biology platform. By generating true causal data from living cells before and after intervention, Cytosurge aims to solve the critical data bottle

Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO 2026 in October

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products. By combining complementary expertise, the collaboration aims to address one of the longstanding challenges in biologic formulation development: the limited availability of excipients suitable for injectable medicines.

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SOT109, the company’s potentially best-in-class antibody-drug conjugate (ADC), for the treatment of patients with advanced unresectable or metastatic colorectal cancer (CRC) who have exhausted standard treatment

A new peer-reviewed study in JCI Insight by DTU and Cytosurge reveals dermokine’s critical role in wound healing and skin cancer. To decode these mechanisms, researchers used Cytosurge’s CellEDIT service to successfully engineer notoriously fragile human keratinocytes. By bypassing the toxicity of traditional bulk transfection, CellEDIT’s vector-free, direct-to-nucleus CRISPR delivery genera

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA action date set for April 23, 2027

Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027

In a collaboration with a leading global pharmaceutical company, Volv Global applied machine learning to 24 million UK primary care records, surfacing approximately 1,200 likely-undiagnosed GEP-NET patients – and finding they are 5–7 years younger than those currently diagnosed. Approximately 1,200 UK patients have records consistent with undiagnosed GEP-NETs – roughly one additional patient

ten23 health, a global contract development and manufacturing organization (CDMO) focused on sterile and biologic drug products, today announced it has successfully obtained GMP certifications for the manufacturing and testing of Advanced Therapy Medicinal Product (ATMP) in its facilities in Basel and Visp, Switzerland.

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced the release of its 2025 Fairstainability Report, underscoring the company’s commitment to transparency, accountability, and responsible innovation across the pharmaceutical services industry.

PharmaBlock has successfully overcome the challenges associated with the application of sec-butyllithium by leveraging continuous flow technology. Following multiple rounds of wet testing, the project achieved continuous and stable operation for more than ten days and successfully completed production and delivery at the hundred-kilogram scale.

Results from prespecified assessment of End of Progression in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentation Evidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented

"Drive For Change," authored by leaders from Volv Global, Sanofi, Fondation Ipsen, Unitechpharma, and brave2change, sets out a strategic roadmap to overcome the systemic barriers holding back rare disease drug development. Approximately 95% of identified rare diseases have no approved treatment, with an economic burden estimated at nearly $1 trillion annually in the United States alone; Drive For

Xlife Sciences AG (SIX: XLS, «Xlife Sciences») a Swiss incubator and accelerator of life sciences companies, today announces that its portfolio company VERAXA Biotech AG («VERAXA») has successfully completed its previously announced business combination with Voyager Acquisition Corp. and will commence trading on the NASDAQ Capital Market under the ticker symbols «VRXA» and «VRXAW» on June

Xenometrix expands its genetic toxicology portfolio with a new, high-quality PB/NF-induced hamster S9 fraction preparation, complemented by dedicated service analysis for laboratories seeking a reliable testing partner.

First-in-human study of  SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma, reinforcing its potential as a

In the largest machine learning study of Pompe disease to date, Volv Global demonstrates that clinician-defined endpoints can be tracked and novel disease features discovered in US claims data across 3,549 patients

Arzanya and leadXpro AG announce a partnership to explore the potential for combining their specific technology platforms and knowledge to discover macrocyclic ligands binding to membrane protein drug targets.

Dr. Felix R. Ehrat and Dr. Peter Jager elected to the Board of Directors at the Annual General Meeting The appointments add governance, capital markets and global pharmaceutical expertise as Topadur advances TOP-N53 and TOP-M119

LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly. LimmaTech’s self-adjuvating and multi-antigen vaccine platform addresses common bacterial infections that currently cannot be prevented Lead program focuses on Staphylococcus aureus infection

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, today announced changes to its leadership team as part of its ongoing commitment to position the company for further long-term growth. These updates reflect a thoughtful alignment of leadership to support the continued expansion of ten23’s capabilities and manuf

Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing

Bionomous releases Sortivo, an automated platform for the gentle screening, sorting and plating of complex biological entities designed to accelerate the adoption of New Approach Methodologies (NAMs).

Mabylon AG, a leader in human-derived, half-life extended multi-specific antibodies, today reported positive Phase IA clinical trial data demonstrating a favorable safety profile of its lead candidate MY006. Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trial in patients. Funding secured for follow-on tree pollen program MY010. The multi-specific antibody

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Cash and cash equival

Total revenues reached a record CHF 7.5 billion in 2025 (CHF 7.2 billion in 2024) with more companies maturing to the commercial stage and a continuously growing demand for specialized CDMO services. Funding increased by 2.1% to CHF 2.6 billion. In a notable shift, investments in privately funded companies achieved a record CHF 1.15 billion – an increase of 38% compared to 2024, and a record 45%

ten23 health, a global contract development and manufacturing organization (CDMO) specializing in sterile fill-finish and advanced drug delivery systems, today announced that it has already successfully tested and ran the newly launched West SynchronyS1 prefillable syringe (PFS) system on its manufacturing equipment.

ALP Bio AG, a Schlieren-based biotech, has closed a CHF 1.75M pre-seed round led by Munich-based 42CAP, with participation from Venture Kick and angel investors. The funding will accelerate ALP Bio's platform, which combines human immune organoid biology with generative AI to help antibody developers identify and reduce immunogenicity risk earlier in drug development.

arcoris bio, an innovative biotech company, and Betta Scientific have entered a strategic collaboration to accelerate global market access of arcoris bio’s multiplex immunofluorescence kits. Leveraging Betta Scientific’s expertise in business-to-consumer strategy and distribution network development, the partnership will expand presence across Europe, APAC, and the Americas.

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release

MastCURe, a high-profile research consortium, has been awarded €1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Immunology and Allergology IA aims to transform the treatment of chronic urticaria, a debilitating mast cell-driven skin disease affecting

ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced the expansion of its commercial activities in the APAC area with the opening of a new office in Tokyo, Japan. This strategic move marks a significant milestone in the company’s global growth and further strengthens its ability to serve biotech and

New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model

Medistri, a leading provider of contract sterilization & laboratory services for healthcare companies, announces its enrollment in the Swiss Good Laboratory Practice (GLP) Compliance Monitoring Programme, effective 13 May 2026. The formal decision was issued by the Notification Authority for Chemicals (NAChem) at the Federal Office of Public Health, following inspections conducted by Swissme

Quant Biomarkers (HK) Limited, a subsidiary of Quant Biomarkers AG, Switzerland, has received approval for admission to the IGNITE (Life & Health Technology) programme at the Hong Kong–Shenzhen Innovation and Technology Park (HSITP), including a milestone-based non-dilutive funding of approximately USD 750,000. The programme supports high-potential health technology companies and provide

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH atta

Lausanne, Switzerland — Leman Biotech Co., Ltd. announced encouraging clinical progress for META 10-19, its proprietary metabolically armored CD19-targeted CAR-T therapy. The first patient with mantle cell lymphoma (MCL) treated without lymphodepleting preconditioning achieved complete remission (CR).

Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda Ramanayake as its new Chief Executive Officer.

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE

Amphasys, a leader in real-time, single‑cell analysis technologies, and Arsenale Bioyards, a neo‑industrial biomanufacturing company pioneering a fully integrated biomanufacturing platform, today announced the signing of a Joint Development Agreement (JDA) to combine their respective technologies into a next‑generation platform for the development and operation of advanced bioprocesses.

Leman Biotech Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for META 10-19, a metabolically armored CD19-targeted CAR-T cell therapy.

Steffen Stürzebecher, MD, PhD, takes on the position of Chief Medical Officer (CMO). He joins the management team of Thomas Christély, CEO, and Marcus Thelen, PhD, CSO.

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints

BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours, and confirming its potentially differentiated profile for the treatment of HAE attacks Final CHAPTER-1 data provide further evidence on long-term safety and efficacy of deucrictibant fo

Helsinn Healthcare SA (Helsinn), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based drug discovery company specializing in AI-powered generative chemistry, today announced a strategic collaboration to discover and develop novel small-molecule therapeutics.

Medistri, a provider of contract sterilization, laboratory, packaging validation, manufacturing, logistics, and consulting services for the healthcare industry, has become a member of Swiss Medtech, the association representing the Swiss MedTech sector.